![]() |
Ovarian Neoplasms |
Free Subscription
|
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Ovarian Neoplasms is free of charge.
GANNET53 Part II: A European Phase I/II Trial of the HSP90 inhibitor Ganetespib
in high-grade Platinum-Resistant Ovarian Cancer - A Study of the GANNET53
consortium.
Clin Cancer Res. 2025 May 28. doi: 10.1158/1078-0432.CCR-24-3705.
PubMed
Abstract available
Patients with advanced ovarian cancer and their experiences and perceptions of
sleep disturbance and fatigue across the treatment trajectory: A qualitative
study.
Gynecol Oncol. 2025;198:42-48.
PubMed
Abstract available
Identification of a novel chemotherapy benefit index for patients with advanced
ovarian cancer based on Bayesian network analysis.
PLoS One. 2025;20:e0322130.
PubMed
Abstract available
Thank you for your interest in scientific medicine.